CA3072536A1 - Hpv vaccine - Google Patents
Hpv vaccine Download PDFInfo
- Publication number
- CA3072536A1 CA3072536A1 CA3072536A CA3072536A CA3072536A1 CA 3072536 A1 CA3072536 A1 CA 3072536A1 CA 3072536 A CA3072536 A CA 3072536A CA 3072536 A CA3072536 A CA 3072536A CA 3072536 A1 CA3072536 A1 CA 3072536A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- conserved
- seq
- nucleic acid
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1713163.2 | 2017-08-16 | ||
| GBGB1713163.2A GB201713163D0 (en) | 2017-08-16 | 2017-08-16 | HPV vaccine |
| PCT/GB2018/052335 WO2019034887A1 (en) | 2017-08-16 | 2018-08-16 | HPV VACCINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3072536A1 true CA3072536A1 (en) | 2019-02-21 |
Family
ID=59895974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3072536A Pending CA3072536A1 (en) | 2017-08-16 | 2018-08-16 | Hpv vaccine |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11179456B2 (enExample) |
| EP (1) | EP3668542A1 (enExample) |
| JP (1) | JP7551495B2 (enExample) |
| KR (1) | KR102713224B1 (enExample) |
| CN (1) | CN111212659B (enExample) |
| AU (1) | AU2018316734B2 (enExample) |
| CA (1) | CA3072536A1 (enExample) |
| GB (1) | GB201713163D0 (enExample) |
| MX (1) | MX2020001655A (enExample) |
| SG (1) | SG11202001244SA (enExample) |
| WO (1) | WO2019034887A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201713163D0 (en) | 2017-08-16 | 2017-09-27 | Univ Oxford Innovation Ltd | HPV vaccine |
| TWI852977B (zh) * | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CA3157667A1 (en) * | 2019-10-16 | 2021-04-22 | Cancer Research Technology Limited | Vector for cancer treatment |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| GB202019767D0 (en) | 2020-12-15 | 2021-01-27 | Chain Biotechnology Ltd | Compostitions and methods |
| GB202209115D0 (en) | 2022-06-21 | 2022-08-10 | Chain Biotechnology Ltd | Compositions and methods |
| WO2024218165A1 (en) * | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
| WO2025092908A1 (zh) * | 2023-11-01 | 2025-05-08 | 仁景(苏州)生物科技有限公司 | 治疗HPV感染相关疾病的mRNA疫苗 |
| CN119464385A (zh) * | 2024-12-04 | 2025-02-18 | 华中科技大学同济医学院附属同济医院 | Matv11重组腺病毒载体、应用、制备方法及hpv治疗性疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| AU2005222776A1 (en) | 2003-12-31 | 2005-09-29 | Genimmune N.V. | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| JP5623910B2 (ja) | 2007-11-02 | 2014-11-12 | ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法 |
| PL2093410T3 (pl) * | 2008-02-21 | 2014-07-31 | Delphi Int Operations Luxembourg Sarl | Wtryskiwacz paliwa z udoskonalonym układem sterującym działaniem zaworu |
| CN102498217A (zh) | 2009-04-20 | 2012-06-13 | 阿波维塔公司 | Hpv的e6蛋白的特异性抗体及其应用 |
| JPWO2014103608A1 (ja) * | 2012-12-25 | 2017-01-12 | 一般財団法人化学及血清療法研究所 | ＨＰＶ／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症及び／又はＢ型肝炎用ワクチン |
| WO2014165291A1 (en) | 2013-03-12 | 2014-10-09 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
| EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201713163D0 (en) | 2017-08-16 | 2017-09-27 | Univ Oxford Innovation Ltd | HPV vaccine |
-
2017
- 2017-08-16 GB GBGB1713163.2A patent/GB201713163D0/en not_active Ceased
-
2018
- 2018-08-16 WO PCT/GB2018/052335 patent/WO2019034887A1/en not_active Ceased
- 2018-08-16 US US16/639,144 patent/US11179456B2/en active Active
- 2018-08-16 CA CA3072536A patent/CA3072536A1/en active Pending
- 2018-08-16 AU AU2018316734A patent/AU2018316734B2/en not_active Expired - Fee Related
- 2018-08-16 MX MX2020001655A patent/MX2020001655A/es unknown
- 2018-08-16 KR KR1020207006062A patent/KR102713224B1/ko active Active
- 2018-08-16 EP EP18759700.0A patent/EP3668542A1/en active Pending
- 2018-08-16 CN CN201880053063.XA patent/CN111212659B/zh active Active
- 2018-08-16 JP JP2020508007A patent/JP7551495B2/ja active Active
- 2018-08-16 SG SG11202001244SA patent/SG11202001244SA/en unknown
-
2021
- 2021-11-22 US US17/532,177 patent/US12064477B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220152189A1 (en) | 2022-05-19 |
| US20200306358A1 (en) | 2020-10-01 |
| AU2018316734B2 (en) | 2025-08-21 |
| KR102713224B1 (ko) | 2024-10-07 |
| CN111212659A (zh) | 2020-05-29 |
| GB201713163D0 (en) | 2017-09-27 |
| CN111212659B (zh) | 2023-09-22 |
| EP3668542A1 (en) | 2020-06-24 |
| JP7551495B2 (ja) | 2024-09-17 |
| KR20200056384A (ko) | 2020-05-22 |
| WO2019034887A1 (en) | 2019-02-21 |
| US11179456B2 (en) | 2021-11-23 |
| US12064477B2 (en) | 2024-08-20 |
| SG11202001244SA (en) | 2020-03-30 |
| JP2020536489A (ja) | 2020-12-17 |
| AU2018316734A1 (en) | 2020-02-27 |
| MX2020001655A (es) | 2020-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3072536A1 (en) | Hpv vaccine | |
| CN111088283B (zh) | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 | |
| JP7098330B2 (ja) | Ｈｐｖワクチン | |
| KR101514473B1 (ko) | 다중 유전자 발현용 벡터 | |
| CN104039833A (zh) | 针对hpv的疫苗 | |
| US20220160853A1 (en) | Cancer vaccine compositions and methods for use thereof | |
| TW200840869A (en) | Papillomavirus vaccine | |
| AU2008249148A1 (en) | Compositions and methods for treating human papillomavirus-mediated disease | |
| KR20090005010A (ko) | Ｈｐｖ-18-기재의 유두종바이러스 백신 | |
| CA2649392A1 (en) | Papillomavirus vaccine | |
| JP2006503914A5 (enExample) | ||
| CA3181431A1 (en) | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease | |
| US20140024017A1 (en) | IDENTIFICATION OF A NOVEL HUMAN POLYOMAVIRUS (IPPyV) AND APPLICATIONS | |
| WO2024218165A1 (en) | Hpv viral vector vaccine | |
| CN102649963B (zh) | 可用于食管癌防治的基于hpv l1基因的重组腺病毒 | |
| US11154613B2 (en) | HCV vaccines | |
| JP2024518565A (ja) | 組換え重複ペプチド及びネイティブタンパク質を含むワクチン製剤 | |
| EP2598520A2 (en) | Recombinant proteins as vaccines for protection against disease induced by infection with mink astrovirus | |
| CN121627808A (zh) | Hpv-52型e6蛋白的特异性ctl表位肽及其应用 | |
| Huber et al. | A Chimeric L1-L2 Virus-like Particle (VLP) Vaccine targeting Common Cutaneous Human Papillomavirus (HPV) Types HPV1 and HPV63 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230816 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240802 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240802 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240802 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240912 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250213 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250620 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250620 |